
May 19 (Reuters) - Prime Medicine Inc PRME.O:
PRIME MEDICINE ANNOUNCES STRATEGIC RESTRUCTURING TO FOCUS ON OPPORTUNITIES IN LARGE GENETIC LIVER DISEASES, CYSTIC FIBROSIS, AND PARTNERED PROGRAMS ALONGSIDE CEO LEADERSHIP TRANSITION
PRIME MEDICINE INC - TO REDUCE HEADCOUNT BY 25%
PRIME MEDICINE INC - ALLAN REINE APPOINTED CEO OF PRIME MEDICINE
PRIME MEDICINE INC - IN ARBITRATION WITH BEAM THERAPEUTICS OVER AATD PROGRAM
PRIME MEDICINE INC: KEITH GOTTESDIENER TO STEP DOWN AS CEO